Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Accounts Payables (2020 - 2025)

Historic Accounts Payables for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $19.0 million.

  • HCW Biologics' Accounts Payables fell 1631.48% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 1631.48%. This contributed to the annual value of $22.3 million for FY2024, which is 26211.21% up from last year.
  • Latest data reveals that HCW Biologics reported Accounts Payables of $19.0 million as of Q3 2025, which was down 1631.48% from $19.4 million recorded in Q2 2025.
  • In the past 5 years, HCW Biologics' Accounts Payables ranged from a high of $22.7 million in Q3 2024 and a low of $743120.0 during Q1 2022
  • Its 5-year average for Accounts Payables is $8.7 million, with a median of $3.3 million in 2021.
  • As far as peak fluctuations go, HCW Biologics' Accounts Payables tumbled by 7326.0% in 2022, and later soared by 61868.42% in 2024.
  • Over the past 5 years, HCW Biologics' Accounts Payables (Quarter) stood at $2.1 million in 2021, then dropped by 17.6% to $1.7 million in 2022, then skyrocketed by 256.42% to $6.2 million in 2023, then surged by 262.11% to $22.3 million in 2024, then dropped by 15.06% to $19.0 million in 2025.
  • Its Accounts Payables stands at $19.0 million for Q3 2025, versus $19.4 million for Q2 2025 and $19.7 million for Q1 2025.